- Calcium & bone metabolism
Big Data Articles (National Health Insurance Service Database)
- Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea
-
Jiwon Kim, Namki Hong, Jimi Choi, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Sin Gon Kim, Cheol Ryong Ku
-
Endocrinol Metab. 2023;38(6):690-700. Published online October 30, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1782
-
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Background
Acromegaly leads to various skeletal complications, and fragility fractures are emerging as a new concern in patients with acromegaly. Therefore, this study investigated the risk of fractures in Korean patients with acromegaly.
Methods We used the Korean nationwide claims database from 2009 to 2019. A total of 931 patients with acromegaly who had never used an osteoporosis drug before and were treated with surgery alone were selected as study participants, and a 1:29 ratio of 26,999 age- and sex-matched osteoporosis drug-naïve controls without acromegaly were randomly selected from the database.
Results The mean age was 46.2 years, and 50.0% were male. During a median follow-up of 54.1 months, there was no difference in the risks of all, vertebral, and non-vertebral fractures between the acromegaly and control groups. However, hip fracture risk was significantly higher (hazard ratio [HR], 2.73; 95% confidence interval [CI], 1.32 to 5.65), and non-hip and non-vertebral fractures risk was significantly lower (HR, 0.40; 95% CI, 0.17 to 0.98) in patients with acromegaly than in controls; these results remained robust even after adjustment for socioeconomic status and baseline comorbidities. Age, type 2 diabetes mellitus, cardio-cerebrovascular disease, fracture history, recent use of acid-suppressant medication, psychotropic medication, and opioids were risk factors for all fractures in patients with acromegaly (all P<0.05).
Conclusion Compared with controls, patients surgically treated for acromegaly had a higher risk of hip fractures. The risk factors for fracture in patients with acromegaly were consistent with widely accepted risk factors in the general population.
- Hypothalamus and pituitary gland
- Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
-
Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee
-
Endocrinol Metab. 2023;38(5):463-471. Published online October 13, 2023
-
DOI: https://doi.org/10.3803/EnM.2023.1820
-
-
1,747
View
-
123
Download
-
1
Crossref
-
Abstract
PDFPubReader ePub
- The clinical characteristics and prognoses of acromegaly vary among patients. Assessment of current and novel predictors can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and a reduction in the increased morbidity and mortality associated with acromegaly. Despite advances in the diagnosis and treatment of acromegaly, its pathophysiology remains unclear. Recent advancements in multiomics technologies, including genomics, transcriptomics, proteomics, metabolomics, and radiomics, have offered new opportunities to unravel the complex pathophysiology of acromegaly. This review comprehensively explores the emerging role of multiomics approaches in elucidating the molecular landscape of acromegaly. We discuss the potential implications of multiomics data integration in the development of novel diagnostic tools, identification of therapeutic targets, and the prospects of precision medicine in acromegaly management. By integrating diverse omics datasets, these approaches can provide valuable insights into disease mechanisms, facilitate the identification of diagnostic biomarkers, and identify potential therapeutic targets for precision medicine in the management of acromegaly.
-
Citations
Citations to this article as recorded by
- “Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?
Lucio Vilar, Luciana Ansaneli Naves, Manoel Ricardo Alves Martins, Antônio Ribeiro-Oliveira Jr Best Practice & Research Clinical Endocrinology & Metabolism.2024; : 101878. CrossRef
- Miscellaneous
- Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
-
Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim, The Committee of Clinical Practice Guideline of the Korean Endocrine Society
-
Endocrinol Metab. 2022;37(6):839-850. Published online December 26, 2022
-
DOI: https://doi.org/10.3803/EnM.2022.1627
-
-
3,553
View
-
321
Download
-
2
Web of Science
-
2
Crossref
-
Abstract
PDFPubReader ePub
- Immune checkpoint inhibitors (ICIs) including an anti-cytotoxic T-lymphocyte-associated antigen 4 inhibitor, anti-programmed cell death protein 1 (PD-1) inhibitors, and anti-PD-ligand 1 inhibitors are representative therapeutics for various malignancies. In oncology, the application of ICIs is currently expanding to a wider range of malignancies due to their remarkable clinical outcomes. ICIs target immune checkpoints which suppress the activity of T-cells that are specific for tumor antigens, thereby allowing tumor cells to escape the immune response. However, immune checkpoints also play a crucial role in preventing autoimmune reactions. Therefore, ICIs targeting immune checkpoints can trigger various immune-related adverse events (irAEs), especially in endocrine organs. Considering the endocrine organs that are frequently involved, irAEs associated endocrinopathies are frequently life-threatening and have unfavorable clinical implications for patients. However, there are very limited data from large clinical trials that would inform the development of clinical guidelines for patients with irAEs associated endocrinopathies. Considering the current clinical situation, in which the scope and scale of the application of ICIs are increasing, position statements from clinical specialists play an essential role in providing the appropriate recommendations based on both medical evidence and clinical experience. As endocrinologists, we would like to present precautions and recommendations for the management of immune-related endocrine disorders, especially those involving the adrenal, thyroid, and pituitary glands caused by ICIs.
-
Citations
Citations to this article as recorded by
- Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population
Ryo Fujiwara, Takeshi yuasa, kenichi kobayashi, tetsuya yoshida, susumu kageyama Expert Review of Anticancer Therapy.2023; 23(5): 461. CrossRef - Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
Won Sang Yoo, Eu Jeong Ku, Eun Kyung Lee, Hwa Young Ahn Endocrinology and Metabolism.2023; 38(6): 750. CrossRef
- Miscellaneous
- COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
-
Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim, the Committee of Clinical Practice Guideline of the Korean Endocrine Society
-
Endocrinol Metab. 2021;36(4):757-765. Published online August 17, 2021
-
DOI: https://doi.org/10.3803/EnM.2021.404
-
-
10,420
View
-
419
Download
-
19
Web of Science
-
21
Crossref
-
Abstract
PDFPubReader ePub
- Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.
-
Citations
Citations to this article as recorded by
- COVID-19 mRNA vaccine may trigger subacute thyroiditis
Mehmet Sözen, Ömercan Topaloğlu, Berrin Çetinarslan, Alev Selek, Zeynep Cantürk, Emre Gezer, Damla Köksalan, Taner Bayraktaroğlu Human Vaccines & Immunotherapeutics.2024; 17(12): 5120. CrossRef - The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
C. Ouaddouh, J.W. Duijster, T. Lieber, F.P.A.M. van Hunsel Expert Opinion on Drug Safety.2024; 23(3): 323. CrossRef - Thyroid dysfunction in COVID-19
David Tak Wai Lui, Chi Ho Lee, Yu Cho Woo, Ivan Fan Ngai Hung, Karen Siu Ling Lam Nature Reviews Endocrinology.2024;[Epub] CrossRef - Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park Journal of Korean Medical Science.2023;[Epub] CrossRef - Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity
Javaria Aslam, Faisal Shahzad Khan, Muhammad Talha Haris, Hewad Hewadmal, Maryam Khalid, Mohammad Y. Alshahrani, Qurrat-ul-ain Aslam, Irrum Aneela, Urooj Zafar Vaccine.2023; 41(2): 598. CrossRef - Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study
Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo Endocrinology and Metabolism.2023; 38(2): 253. CrossRef - Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo Journal of Clinical Medicine.2023; 12(14): 4799. CrossRef - Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves’ disease: An observational cohort study
Shichen Xu, Huixin Yu, Xian Cheng, Jing Wu, Jiandong Bao, Li Zhang Vaccine.2023; 41(38): 5648. CrossRef - Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency
Yukako Kurematsu, Takako Mohri, Sadanori Okada, Yutaka Takahashi JCEM Case Reports.2023;[Epub] CrossRef - Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional Study
İbrahim Mert Erbaş, İrem Ceren Erbaş, Gözde Akın Kağızmanlı, Kübra Yüksek Acinikli, Özge Besci, Korcan Demir, Ece Böber, Nurşen Belet, Ayhan Abacı Journal of Clinical Research in Pediatric Endocrinology.2023; 15(3): 248. CrossRef - Neue Aspekte der Glukokortikoidsubstitution bei Nebennierenrindeninsuffizienz
Tina Kienitz, Gesine Meyer Der Internist.2022; 63(1): 12. CrossRef - Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence
Rimesh Pal, Ameya Joshi, Sanjay K. Bhadada, Mainak Banerjee, Suresh Vaikkakara, Satinath Mukhopadhyay Endocrine Practice.2022; 28(4): 425. CrossRef - Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study
Xi Xiong, Carlos King Ho Wong, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Franco Wing Tak Cheng, Kristy Tsz Kwan Lau, Chi Ho Lee, Yu Cho Woo, David Tak Wai Lui, Ian Chi Kei Wong Thyroid.2022; 32(5): 505. CrossRef - The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea Diagnostics.2022; 12(4): 960. CrossRef - Adrenal Crisis Secondary to COVID-19 Vaccination in a Patient With Hypopituitarism
Nikolina Markovic, Anila Faizan, Chirag Boradia, Sridhar Nambi AACE Clinical Case Reports.2022; 8(4): 171. CrossRef - The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
LingHong Huang, ZhengRong Jiang, JingXiong Zhou, YuPing Chen, HuiBin Huang Frontiers in Endocrinology.2022;[Epub] CrossRef - Osteoporosis in Patients With Respiratory Diseases
Yue Ma, Shui Qiu, Renyi Zhou Frontiers in Physiology.2022;[Epub] CrossRef - Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology
Ach Taieb, El Euch Mounira Vaccines.2022; 10(12): 2004. CrossRef - Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
Jong Chul Won, Ki-Hyun Baek Endocrinology and Metabolism.2022; 37(6): 851. CrossRef - No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine
Tania Pilli, Cristina Dalmiglio, Gilda Dalmazio, Alfonso Sagnella, Raffaella Forleo, Lucia Brilli, Fabio Maino, Cristina Ciuoli, Maria Grazia Castagna European Journal of Endocrinology.2022; 187(1): K7. CrossRef - Diabetes and COVID-19 Vaccination
Hae Dong Choi, Jun Sung Moon The Journal of Korean Diabetes.2021; 22(4): 221. CrossRef
- Clinical Study
- Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma
-
Hyein Jung, Kyungwon Kim, Daham Kim, Ju Hyung Moon, Eui Hyun Kim, Se Hoon Kim, Cheol Ryong Ku, Eun Jig Lee
-
Endocrinol Metab. 2021;36(2):342-350. Published online March 23, 2021
-
DOI: https://doi.org/10.3803/EnM.2020.875
-
-
4,382
View
-
145
Download
-
4
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader ePub
- Background
The guanine nucleotide-binding protein, alpha stimulating (GNAS) gene has been associated with growth hormone (GH)-secreting pituitary adenoma. We investigated the prevalence of GNAS mutations in Korean patients with acromegaly and assessed whether mutation status correlated with biochemical or clinical characteristics.
Methods We studied 126 patients with acromegaly who underwent surgery between 2005 and 2014 at Severance Hospital. We performed GNAS gene analysis and evaluated age, sex, hormone levels, postoperative biochemical remission, and immunohistochemical staining results of the tumor.
Results GNAS mutations were present in 75 patients (59.5%). Patients with and without GNAS mutations showed similar age distribution and Knosp classification. The proportion of female patients was 76.5% and 48.0% in the GNAS-negative and GNAS-mutation groups, respectively (P=0.006). In immunohistochemical staining, the GNAS-mutation group showed higher GH expression in pituitary tumor tissues than the mutation-negative group (98.7% vs. 92.2%, P=0.015). Patients with GNAS mutations had higher preoperative insulin-like growth factor-1 levels (791.3 ng/mL vs. 697.0 ng/mL, P=0.045) and lower immediate postoperative basal (0.9 ng/mL vs. 1.0 ng/mL, P=0.191) and nadir GH levels (0.3 ng/mL vs. 0.6 ng/mL, P=0.012) in oral glucose tolerance tests. Finally, the GNAS-mutation group showed significantly higher surgical remission rates than the mutation-negative group, both at 1 week and 6 months after surgical resection (70.7% vs. 54.9%, P=0.011; 85.3% vs. 82.4%, P=0.007, respectively).
Conclusion GNAS mutations in GH-secreting pituitary tumors are associated with higher preoperative insulin-like growth factor-1 levels and surgical remission rates and lower immediate postoperative nadir GH levels. Thus, GNAS mutation status can predict surgical responsiveness in patients with acromegaly.
-
Citations
Citations to this article as recorded by
- Genetic diagnosis in acromegaly and gigantism: From research to clinical practice
Claudia Ramírez-Rentería, Laura C. Hernández-Ramírez Best Practice & Research Clinical Endocrinology & Metabolism.2024; : 101892. CrossRef - CD8/PD-L1 immunohistochemical reactivity and gene alterations in cutaneous squamous cell carcinoma
Haruto Nishida, Yoshihiko Kondo, Takahiro Kusaba, Kazuhiro Kawamura, Yuzo Oyama, Tsutomu Daa, Avaniyapuram Kannan Murugan PLOS ONE.2023; 18(2): e0281647. CrossRef - Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC
Xiya Ma, Kun Zhang, Jing Xu, Hongjun Gao, Shaoxing Yang, Haifeng Qin, Hong Wang, Fang Gao, Xiaoqing Liu Thoracic Cancer.2023; 14(20): 1980. CrossRef - Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee Endocrinology and Metabolism.2023; 38(5): 463. CrossRef - Hotspots of Somatic Genetic Variation in Pituitary Neuroendocrine Tumors
Mariana Torres-Morán, Alexa L. Franco-Álvarez, Rosa G. Rebollar-Vega, Laura C. Hernández-Ramírez Cancers.2023; 15(23): 5685. CrossRef
- Endocrine Research
- Danshen Extracts Prevents Obesity and Activates Mitochondrial Function in Brown Adipose Tissue
-
Yoon Hee Cho, Cheol Ryong Ku, Young-Suk Choi, Hyeon Jeong Lee, Eun Jig Lee
-
Endocrinol Metab. 2021;36(1):185-195. Published online February 24, 2021
-
DOI: https://doi.org/10.3803/EnM.2020.835
-
-
4,668
View
-
132
Download
-
1
Web of Science
-
1
Crossref
-
Abstract
PDFPubReader ePub
- Background
Danshen has been widely used in oriental medicine to improve body function. The purpose of this study is to investigate the effect of water-soluble Danshen extract (DE) on weight loss and on activation proteins involved in mitochondrial biogenesis in brown adipose tissue (BAT) in obese mice.
Methods BAT was isolated from 7-week-old male Sprague-Dawley rats, and expression of proteins related to mitochondrial biogenesis was confirmed in both brown preadipocytes and mature brown adipocytes treated with DE. For the in vivo study, low-density lipoprotein receptor knock out mice were divided into three groups and treated for 17 weeks with: standard diet; high fat diet (HFD); HFD+DE. Body weight was measured every week, and oral glucose tolerance test was performed after DE treatment in streptozotocin-induced diabetic mice. To observe the changes in markers related to thermogenesis and adipogenesis in the BAT, white adipose tissue (WAT) and liver of experimental animals, tissues were removed and immediately frozen in liquid nitrogen.
Results DE increased the expression of uncoupling protein 1 and peroxisome proliferator-activated receptor gamma coactivator 1-alpha in brown preadipocytes, and also promoted the brown adipocyte differentiation and mitochondrial function in the mature brown adipocytes. Reactive oxygen species production in brown preadipocytes was increased depending on the concentration of DE. DE activates thermogenesis in BAT and normalizes increased body weight and adipogenesis in the liver due to HFD. Browning of WAT was increased in WAT of DE treatment group.
Conclusion DE protects against obesity and activates mitochondrial function in BAT.
-
Citations
Citations to this article as recorded by
- Pharmacological Benefits and Underlying Mechanisms of Salvia miltiorrhiza against Molecular Pathology of Various Liver Diseases: A Review
Cho Hyun Hwang, Eungyeong Jang, Jang-Hoon Lee The American Journal of Chinese Medicine.2023; 51(07): 1675. CrossRef
- Hypothalamus and Pituitary gland
- Establishment of Reference Intervals for Serum Insulin-Like Growth Factor I in Korean Adult Population
-
Boyeon Kim, Yonggeun Cho, Cheol Ryong Ku, Sang-Guk Lee, Kyung-A Lee, Jeong-Ho Kim
-
Endocrinol Metab. 2020;35(4):960-964. Published online November 20, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.732
-
-
4,805
View
-
107
Download
-
4
Web of Science
-
3
Crossref
-
Abstract
PDFSupplementary MaterialPubReader ePub
- Appropriate reference intervals of serum insulin-like growth factor I (IGF-I) is important for diagnosing and monitoring patients with growth hormone-related diseases. To establish reference intervals, adult individuals (n=1,334, 680 men and 654 women) were divided into six age groups (20–29, 30–39, 40–49, 50–59, 60–69, ≥70). Serum IGF-I was measured by chemiluminescence immunoassay (Liaison). Concordance of patient classification based on reference intervals, manufacturer’s intervals, and standard deviation score (SDS) was evaluated. New reference intervals had higher upper and lower limits than those specified by the manufacturer. The agreement between classification using new reference interval and the manufacturer’s reference interval, and that using new reference interval and SDS was 75.0% (weighted kappa, 0.17), 91.9% (weighted kappa, 0.51) in men and 91.0% (weighted kappa, 0.41), 92.5% (weighted kappa, 0.53) in women, respectively. Reference intervals should be established not only based on age and sex, but also on ethnicity and assay method.
-
Citations
Citations to this article as recorded by
- Challenges of insulin-like growth factor-1 testing
Rongrong Huang, Junyan Shi, Ruhan Wei, Jieli Li Critical Reviews in Clinical Laboratory Sciences.2024; : 1. CrossRef - Male idiopathic hypogonadotropic hypogonadism: Serum insulin-like growth factor-1 and oestradiol levels
Nastaran Salehisedeh, Amir Parhizkar, Parichehreh Yaghmaei, Marjan Sabbaghian Journal of Human Reproductive Sciences.2022; 15(4): 351. CrossRef - Revisiting the Role of Insulin-like Growth Factor-1 Measurement After Surgical Treatment of Acromegaly
In-Ho Jung, Seonah Choi, Cheol Ryong Ku, Sang-Guk Lee, Eun Jig Lee, Sun Ho Kim, Eui Hyun Kim The Journal of Clinical Endocrinology & Metabolism.2021; 106(7): e2589. CrossRef
- Hypothalamus and Pituitary gland
- Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
-
Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee
-
Endocrinol Metab. 2020;35(2):206-216. Published online June 24, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.35.2.206
-
-
6,778
View
-
252
Download
-
8
Web of Science
-
8
Crossref
-
Abstract
PDFPubReader ePub
- Acromegaly presents with an enigmatic range of symptoms and comorbidities caused by chronic and progressive growth hormone elevations, commonly due to endocrinologic hypersecretion from a pituitary gland tumor. Comprehensive national acromegaly databases have been appearing over the years, allowing for international comparisons of data, although still presenting varying prevalence and incidence rates. Lack of large-scale analysis in geographical and ethnic differences in clinical presentation and management requires further research. Assessment of current and novel predictors of responsiveness to distinct therapy can lead to multilevel categorization of patients, allowing integration into new clinical guidelines and reduction of increased morbidity and mortality associated with acromegaly. This review compares current data from epidemiological studies and assesses the present-day application of prognostic factors in medical practice, the reality of precision therapy, as well as its future prospects in acromegaly, with a special focus on its relevance to the South Korean population.
-
Citations
Citations to this article as recorded by
- Biomarkers of response to treatment in acromegaly
Leandro Kasuki, Elisa Lamback, Ximene Antunes, Mônica R. Gadelha Expert Review of Endocrinology & Metabolism.2024; 19(1): 71. CrossRef - Multiomics Approach to Acromegaly: Unveiling Translational Insights for Precision Medicine
Kyungwon Kim, Cheol Ryong Ku, Eun Jig Lee Endocrinology and Metabolism.2023; 38(5): 463. CrossRef - Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study
Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park European Journal of Endocrinology.2023; 189(3): 363. CrossRef - The Future of Somatostatin Receptor Ligands in Acromegaly
Monica R Gadelha, Luiz Eduardo Wildemberg, Leandro Kasuki The Journal of Clinical Endocrinology & Metabolism.2022; 107(2): 297. CrossRef - Innovative therapeutics in acromegaly
Leandro Kasuki, Mônica R. Gadelha Best Practice & Research Clinical Endocrinology & Metabolism.2022; 36(6): 101679. CrossRef - Risk of Neurodegenerative Diseases in Patients With Acromegaly
Sangmo Hong, Kyungdo Han, Kyung-Soo Kim, Cheol-Young Park Neurology.2022;[Epub] CrossRef - Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands
Luiz Eduardo Wildemberg, Aline Helen da Silva Camacho, Renan Lyra Miranda, Paula C L Elias, Nina R de Castro Musolino, Debora Nazato, Raquel Jallad, Martha K P Huayllas, Jose Italo S Mota, Tobias Almeida, Evandro Portes, Antonio Ribeiro-Oliveira, Lucio Vi The Journal of Clinical Endocrinology & Metabolism.2021; 106(7): 2047. CrossRef - Skin anomalies in acromegalic patients (Review of the practical aspects)
Florica Sandru, Adelina Popa, Dan Paduraru, Alexandru Filipescu, Mara Carsote, Adina Ghemigian Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
- Miscellaneous
- Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology
-
Jung Hee Kim, Hyun Wook Chae, Sang Ouk Chin, Cheol Ryong Ku, Kyeong Hye Park, Dong Jun Lim, Kwang Joon Kim, Jung Soo Lim, Gyuri Kim, Yun Mi Choi, Seong Hee Ahn, Min Ji Jeon, Yul Hwangbo, Ju Hee Lee, Bu Kyung Kim, Yong Jun Choi, Kyung Ae Lee, Seong-Su Moon, Hwa Young Ahn, Hoon Sung Choi, Sang Mo Hong, Dong Yeob Shin, Ji A Seo, Se Hwa Kim, Seungjoon Oh, Sung Hoon Yu, Byung Joon Kim, Choong Ho Shin, Sung-Woon Kim, Chong Hwa Kim, Eun Jig Lee
-
Endocrinol Metab. 2020;35(2):272-287. Published online June 24, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.35.2.272
-
-
9,536
View
-
431
Download
-
14
Web of Science
-
16
Crossref
-
Abstract
PDFPubReader ePub
- Growth hormone (GH) deficiency is caused by congenital or acquired causes and occurs in childhood or adulthood. GH replacement therapy brings benefits to body composition, exercise capacity, skeletal health, cardiovascular outcomes, and quality of life. Before initiating GH replacement, GH deficiency should be confirmed through proper stimulation tests, and in cases with proven genetic causes or structural lesions, repeated GH stimulation testing is not necessary. The dosing regimen of GH replacement therapy should be individualized, with the goal of minimizing side effects and maximizing clinical improvements. The Korean Endocrine Society and the Korean Society of Pediatric Endocrinology have developed a position statement on the diagnosis and treatment of GH deficiency. This position statement is based on a systematic review of evidence and expert opinions.
-
Citations
Citations to this article as recorded by
- Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
Ghina Tsurayya, Cut Alifiya Nazhifah, Muhammad Rahmat Pirwanja, Putri Oktaviani Zulfa, Muhammad Raihan Ramadhan Tatroman, Fajar Fakri, Muhammad Iqhrammullah Children.2024; 11(2): 227. CrossRef - Efficacy, safety, and patient satisfaction of norditropin and sogroya in patients with growth hormone deficiency: a systematic review and meta-analysis of randomized controlled trials
Obieda Altobaishat, Mohamed Abouzid, Mostafa Hossam El Din Moawad, Abdulrahman Sharaf, Yazan Al-Ajlouni, Tungki Pratama Umar, Abdallah Bani-salameh, Mohammad Tanashat, Omar Abdullah Bataineh, Abdulqadir J. Nashwan Endocrine.2024;[Epub] CrossRef - Evaluation of Adult Height in Patients with Non-Permanent Idiopathic GH Deficiency
Agnese Murianni, Anna Lussu, Chiara Guzzetti, Anastasia Ibba, Letizia Casula, Mariacarolina Salerno, Marco Cappa, Sandro Loche Endocrines.2023; 4(1): 169. CrossRef - The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma
Sang Hee Park, Yun Jeong Lee, Jung-Eun Cheon, Choong Ho Shin, Hae Woon Jung, Young Ah Lee Annals of Pediatric Endocrinology & Metabolism.2023; 28(2): 107. CrossRef - Continuous Glucose Monitoring: A Possible Aid for Detecting Hypoglycemic Events during Insulin Tolerance Tests
Soo Yeun Sim, Moon Bae Ahn Sensors.2023; 23(15): 6892. CrossRef - The risk patients with AGHD have of developing CVD
Eisha Javed, Maha Zehra, Naz Elahi International Journal of Cardiology Cardiovascular Risk and Prevention.2023; 19: 200221. CrossRef - Diagnosis of GH Deficiency Without GH Stimulation Tests
Anastasia Ibba, Sandro Loche Frontiers in Endocrinology.2022;[Epub] CrossRef - Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
Yun Jeong Lee, Yunha Choi, Han-Wook Yoo, Young Ah Lee, Choong Ho Shin, Han Saem Choi, Ho-Seong Kim, Jae Hyun Kim, Jung Eun Moon, Cheol Woo Ko, Moon Bae Ahn, Byung-Kyu Suh, Jin-Ho Choi Endocrinology and Metabolism.2022; 37(2): 359. CrossRef - A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI
Taeyoun Lee, Kyungchul Song, Beomseok Sohn, Jihwan Eom, Sung Soo Ahn, Ho-Seong Kim, Seung-Koo Lee Yonsei Medical Journal.2022; 63(9): 856. CrossRef - Phenotypic spectrum of patients with mutations in CHD7: clinical implications of endocrinological findings
Ja Hye Kim, Yunha Choi, Soojin Hwang, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi Endocrine Connections.2022;[Epub] CrossRef - Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim Endocrinology and Metabolism.2022; 37(6): 839. CrossRef - Laron syndrome: clinic, diagnostics (а clinical case)
P.M. Lіashuk, R.P. Lіashuk, N.I. Stankova, M.B. Kudina INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 193. CrossRef - Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan Endocrinology and Metabolism.2021; 36(2): 322. CrossRef - Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
Byung Kwan Park, Masashi Fujimori, Shu-Huei Shen, Uei Pua Endocrinology and Metabolism.2021; 36(3): 553. CrossRef - Asian Conference on Tumor Ablation guidelines for renal cell carcinoma
Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, Yi Wang Investigative and Clinical Urology.2021; 62(4): 378. CrossRef - Diagnosis and Treatment of Adult Growth Hormone Deficiency
Jung Hee Kim The Korean Journal of Medicine.2021; 96(5): 400. CrossRef
- Endocrine Research
- Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas
-
Jean Kim, Ju Hun Oh, Heather Harlem, Michael D. Culler, Cheol Ryong Ku, Eun Jig Lee
-
Endocrinol Metab. 2020;35(1):177-187. Published online March 19, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.35.1.177
-
-
4,528
View
-
106
Download
-
4
Web of Science
-
5
Crossref
-
Abstract
PDFPubReader ePub
- Background
Acromegaly is a rare disease primarily caused by growth hormone (GH)-secreting pituitary adenomas, and its treatment is costly. Moreover, some patients are unresponsive to treatment. Hence, there are increasing efforts to develop new drugs with improved effectiveness for this disease. BIM23B065 is a novel chimeric molecule that acts on both somatostatin and dopamine receptors. This study aimed to investigate the effects of BIM23B065 compared with those of a somatostatin receptor analog and a dopamine agonist. MethodsThe effects of BIM23B065 on the proliferation, GH and insulin-like growth factor-1 (IGF-1) levels, and extracellular signal-regulated kinase (ERK) 1/2 and cyclic AMP response element binding (CREB) phosphorylation of GH3 cells were investigated with MTS assay, enzyme-linked immunosorbent assay, and Western blotting, respectively. The dosage and treatment duration of BIM23B065 were tested in animal models of GH-secreting pituitary adenoma. The effect of BIM23B065 (3 mg/kg/day) on changes in IGF-1 levels before and after treatment was further investigated. ResultsIn vitro, BIM23B065 treatment decreased GH release in the culture media and downregulated ERK 1/2 and CREB phosphorylation to 22% and 26%, respectively. In vivo, IGF-1 expression decreased to 50 % after 4 weeks of treatment with BIM23B065 using an osmotic pump implant. Moreover, magnetic resonance imaging results showed that the tumor size decreased significantly following treatment with BIM23B065 for 4 weeks. ConclusionThe novel chimeric molecule was effective in decreasing IGF-1 and GH levels and may serve as an effective therapeutic agent for acromegaly.
-
Citations
Citations to this article as recorded by
- Pituitary Tumorigenesis—Implications for Management
Rodanthi Vamvoukaki, Maria Chrysoulaki, Grigoria Betsi, Paraskevi Xekouki Medicina.2023; 59(4): 812. CrossRef - Current and Emerging Medical Therapies in Pituitary Tumors
Nicolas Sahakian, Frédéric Castinetti, Thierry Brue, Thomas Cuny Journal of Clinical Medicine.2022; 11(4): 955. CrossRef - Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells
Thomas Cuny, Thomas Graillon, Célines Defilles, Rakesh Datta, Shengwen Zhang, Dominique Figarella-Branger, Henry Dufour, Grégory Mougel, Thierry Brue, Tanya Landsman, Heather A. Halem, Michael D. Culler, Anne Barlier, Alexandru Saveanu Pituitary.2021; 24(3): 351. CrossRef - Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study
Alessandra Dicitore, Maria Celeste Cantone, Germano Gaudenzi, Davide Saronni, Silvia Carra, Maria Orietta Borghi, Manuela Albertelli, Diego Ferone, Leo J. Hofland, Luca Persani, Giovanni Vitale Neuroendocrinology.2021; 111(10): 937. CrossRef - Emerging drugs for the treatment of acromegaly
Claudia Campana, Giuliana Corica, Federica Nista, Francesco Cocchiara, Giulia Graziani, Keyvan Khorrami, Marta Franco, Mara Boschetti, Diego Ferone, Federico Gatto Expert Opinion on Emerging Drugs.2020; 25(4): 409. CrossRef
- Hypothalamus and Pituitary gland
- Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
-
Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong Jun Lim, Dong Yeob Shin, Se Hwa Kim, Min Jeong Kwon, Ha Young Kim, Jin Hwa Kim, Dong Sun Kim, Chong Hwa Kim
-
Endocrinol Metab. 2019;34(1):53-62. Published online March 21, 2019
-
DOI: https://doi.org/10.3803/EnM.2019.34.1.53
-
-
6,493
View
-
255
Download
-
8
Web of Science
-
11
Crossref
-
Abstract
PDFPubReader ePub
The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
-
Citations
Citations to this article as recorded by
- Hydrogel-fiber-mesh-based 3D cell cultures: A new method for studying pituitary tumors
Wooju Jeong, Sungrok Wang, Yumin Kim, Soohyun Lee, Minhu Huang, Jaeil Park, Myung-Han Yoon, Chang-Myung Oh, Cheol Ryong Ku Smart Materials in Medicine.2024;[Epub] CrossRef - Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association
A Ram Hong, Ho-Cheol Kang Endocrinology and Metabolism.2023; 38(2): 175. CrossRef - Growth Hormone Excess: Implications and Management
Suneela Dhaneshwar, Shrishti Shandily, Vatsalya Tiwari Endocrine, Metabolic & Immune Disorders - Drug Targets.2023; 23(6): 748. CrossRef - Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Montserrat Marques-Pamies, Joan Gil, Elena Valassi, Marta Hernández, Betina Biagetti, Olga Giménez-Palop, Silvia Martínez, Cristina Carrato, Laura Pons, Rocío Villar-Taibo, Marta Araujo-Castro, Concepción Blanco, Inmaculada Simón, Andreu Simó-Servat, Gemm Frontiers in Endocrinology.2023;[Epub] CrossRef - Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang International Journal of Thyroidology.2022; 15(1): 1. CrossRef - Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy
I. A. Ilovayskaya Meditsinskiy sovet = Medical Council.2022; (10): 148. CrossRef - Approach of Acromegaly during Pregnancy
Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascălu, Tiberiu Tircă, Jaqueline Abdul-Razzak, Mihaela Jana Țuculină Diagnostics.2022; 12(11): 2669. CrossRef - Left to themselves: Time to target chronic pain in childhood rare diseases
Christine B. Sieberg, Alyssa Lebel, Erin Silliman, Scott Holmes, David Borsook, Igor Elman Neuroscience & Biobehavioral Reviews.2021; 126: 276. CrossRef - Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide
Jacob Luty, LesleAnn Hayward, Melanie Jackson, P Barton Duell BMJ Case Reports.2021; 14(8): e243900. CrossRef - Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee Endocrinology and Metabolism.2020; 35(2): 206. CrossRef - Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong The Korean Journal of Medicine.2019; 94(6): 485. CrossRef
- Obesity and Metabolism
- Response: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab 2016;31:328-35, Cheol Ryong Ku et al.)
-
Cheol Ryong Ku, Eun Jig Lee
-
Endocrinol Metab. 2016;31(3):482-483. Published online September 26, 2016
-
DOI: https://doi.org/10.3803/EnM.2016.31.3.482
-
-
2,600
View
-
26
Download
-
1
Web of Science
-
1
Crossref
-
PDFPubReader
-
Citations
Citations to this article as recorded by
- Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor
Clara Lefranc, Malou Friederich-Persson, Roberto Palacios-Ramirez, Aurelie Nguyen Dinh Cat Journal of Endocrinology.2018; 238(3): R143. CrossRef
- Endocrine Research
- The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes
-
Cheol Ryong Ku, Yoon Hee Cho, Zhen-Yu Hong, Ha Lee, Sue Ji Lee, Seung-soo Hong, Eun Jig Lee
-
Endocrinol Metab. 2016;31(2):328-335. Published online April 8, 2016
-
DOI: https://doi.org/10.3803/EnM.2016.31.2.328
-
-
4,172
View
-
50
Download
-
25
Web of Science
-
25
Crossref
-
Abstract
PDFPubReader
- Background
Resveratrol (RSV) is a polyphenolic phytoalexin that has many effects on metabolic diseases such as diabetes and obesity. Given the importance of brown adipose tissue (BAT) for energy expenditure, we investigated the effects of RSV on brown adipocytes. MethodsFor the in vitro study, interscapular BAT was isolated from 7-week-old male Sprague Dawley rats. For the in vivo study, 7-week-old male Otsuka Long Evans Tokushima Fatty (OLETF) rats were divided into four groups and treated for 27 weeks with: standard diet (SD); SD+RSV (10 mg/kg body weight, daily); high fat diet (HFD); HFD+RSV. RSV was provided via oral gavage once daily during the in vivo experiments. ResultsRSV treatment of primary cultured brown preadipocytes promoted mitochondrial activity, along with over-expression of estrogen receptor α (ER-α). In OLETF rats, both HFD and RSV treatment increased the weight of BAT and the differentiation of BAT. However, only RSV increased the mitochondrial activity and ER-α expression of BAT in the HFD-fed group. Finally, RSV improved the insulin sensitivity of OLETF rats by increasing the mitochondrial activity of BAT, despite having no effects on white adipocytes and muscles in either diet group. ConclusionRSV could improve insulin resistance, which might be associated with mitochondrial activity of brown adipocyte. Further studies evaluating the activity of RSV for both the differentiation and mitochondrial activity of BAT could be helpful in investigating the effects of RSV on metabolic parameters.
-
Citations
Citations to this article as recorded by
- Natural Bioactive Compounds from Foods Inhibited Pigmentation Especially Potential Application of Fucoxanthin to Chloasma: a Mini-Review
Yida Wang, Hang Qi Food Reviews International.2024; 40(1): 20. CrossRef - Resveratrol combats chronic diseases through enhancing mitochondrial quality
Weichu Tao, Hu Zhang, Xia Jiang, Ning Chen Food Science and Human Wellness.2024; 13(2): 597. CrossRef - The Potential to Fight Obesity with Adipogenesis Modulating Compounds
Jiaqi Zhao, Ailin Zhou, Wei Qi International Journal of Molecular Sciences.2022; 23(4): 2299. CrossRef - Macrophage and Adipocyte Mitochondrial Dysfunction in Obesity-Induced Metabolic Diseases
Liwen Wang, Jie Hu, Haiyan Zhou The World Journal of Men's Health.2021; 39(4): 606. CrossRef - Precision Nutrition to Activate Thermogenesis as a Complementary Approach to Target Obesity and Associated-Metabolic-Disorders
Marina Reguero, Marta Gómez de Cedrón, Sonia Wagner, Guillermo Reglero, José Carlos Quintela, Ana Ramírez de Molina Cancers.2021; 13(4): 866. CrossRef - Natural Antioxidant Application on Fat Accumulation: Preclinical Evidence
Proshanta Roy, Daniele Tomassoni, Enea Traini, Ilenia Martinelli, Maria Vittoria Micioni Di Bonaventura, Carlo Cifani, Francesco Amenta, Seyed Khosrow Tayebati Antioxidants.2021; 10(6): 858. CrossRef - Activation of Brown Adipose Tissue and Promotion of White Adipose Tissue Browning by Plant-based Dietary Components in Rodents: A Systematic Review
Francisco J Osuna-Prieto, Borja Martinez-Tellez, Antonio Segura-Carretero, Jonatan R Ruiz Advances in Nutrition.2021; 12(6): 2147. CrossRef - Role of Dietary Polyphenols in Adipose Tissue Browning: A Narrative Review
Juan Salazar, Clímaco Cano, José L. Pérez, Ana Castro, María P. Díaz, Bermary Garrido, Rubén Carrasquero, Maricarmen Chacín, Manuel Velasco, Luis D´Marco, Joselyn Rojas-Quintero, Valmore Bermúdez Current Pharmaceutical Design.2020; 26(35): 4444. CrossRef - Brown and Brite: The Fat Soldiers in the Anti-obesity Fight
Shireesh Srivastava, Richard L. Veech Frontiers in Physiology.2019;[Epub] CrossRef - Effect of resveratrol on adipokines and myokines involved in fat browning: Perspectives in healthy weight against obesity
Oh Yoen Kim, Ji Yeon Chung, Juhyun Song Pharmacological Research.2019; 148: 104411. CrossRef - Ginsenoside Rb2 Alleviates Obesity by Activation of Brown Fat and Induction of Browning of White Fat
Yilian Hong, Yi Lin, Qiya Si, Lijuan Yang, Weisong Dong, Xuejiang Gu Frontiers in Endocrinology.2019;[Epub] CrossRef - Programming of the Beige Phenotype in White Adipose Tissue of Adult Mice by Mild Resveratrol and Nicotinamide Riboside Supplementations in Early Postnatal Life
Alba Serrano, Madhu Asnani-Kishnani, Ana María Rodríguez, Andreu Palou, Joan Ribot, María Luisa Bonet Molecular Nutrition & Food Research.2018;[Epub] CrossRef - Effects of Polyphenols on Thermogenesis and Mitochondrial Biogenesis
Tanila Wood dos Santos, Quélita Cristina Pereira, Lucimara Teixeira, Alessandra Gambero, Josep A. Villena, Marcelo Lima Ribeiro International Journal of Molecular Sciences.2018; 19(9): 2757. CrossRef - Programming mediated by fatty acids affects uncoupling protein 1 (UCP-1) in brown adipose tissue
Perla P. Argentato, Helena de Cássia César, Débora Estadella, Luciana P. Pisani British Journal of Nutrition.2018; 120(6): 619. CrossRef - Effects of Genistein on Differentiation and Viability of Human Visceral Adipocytes
Elena Grossini, Serena Farruggio, Giulia Raina, David Mary, Giacomo Deiro, Sergio Gentilli Nutrients.2018; 10(8): 978. CrossRef - A comprehensive review of the health perspectives of resveratrol
Abdur Rauf, Muhammad Imran, Hafiz Ansar Rasul Suleria, Bashir Ahmad, Dennis G. Peters, Mohammad S. Mubarak Food & Function.2017; 8(12): 4284. CrossRef - The Role of Circulating Slit2, the One of the Newly Batokines, in Human Diabetes Mellitus
Yea Eun Kang, Sorim Choung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku Endocrinology and Metabolism.2017; 32(3): 383. CrossRef - A nutritional perspective on UCP1-dependent thermogenesis
M. Luisa Bonet, Josep Mercader, Andreu Palou Biochimie.2017; 134: 99. CrossRef - The Beneficial Effects of Quercetin, Curcumin, and Resveratrol in Obesity
Yueshui Zhao, Bo Chen, Jing Shen, Lin Wan, Yinxin Zhu, Tao Yi, Zhangang Xiao Oxidative Medicine and Cellular Longevity.2017; 2017: 1. CrossRef - Articles inEndocrinology and Metabolismin 2016
Won-Young Lee Endocrinology and Metabolism.2017; 32(1): 62. CrossRef - Antiobesity effects of resveratrol: which tissues are involved?
Alfredo Fernández‐Quintela, Iñaki Milton‐Laskibar, Marcela González, Maria P. Portillo Annals of the New York Academy of Sciences.2017; 1403(1): 118. CrossRef - Resveratrol attenuates triglyceride accumulation associated with upregulation of Sirt1 and lipoprotein lipase in 3T3-L1 adipocytes
Haruki Imamura, Daiji Nagayama, Noriko Ishihara, Syo Tanaka, Rena Watanabe, Yasuhiro Watanabe, Yuta Sato, Takashi Yamaguchi, Noriko Ban, Hidetoshi Kawana, Masahiro Ohira, Kei Endo, Atsuhito Saiki, Kohji Shirai, Ichiro Tatsuno Molecular Genetics and Metabolism Reports.2017; 12: 44. CrossRef - Resveratrol has dose-dependent effects on DNA fragmentation and mitochondrial activity of ovine secondary follicles cultured in vitro
T.J.S. Macedo, V.R.P. Barros, A.P.O. Monte, B.B. Gouveia, M.É.S. Bezerra, A.Y.P. Cavalcante, R.S. Barberino, V.G. Menezes, M.H.T. Matos Zygote.2017; 25(4): 434. CrossRef - Response: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab2016;31:328-35, Cheol Ryong Ku et al.)
Cheol Ryong Ku, Eun Jig Lee Endocrinology and Metabolism.2016; 31(3): 482. CrossRef - Letter: The Effects of High Fat Diet and Resveratrol on Mitochondrial Activity of Brown Adipocytes (Endocrinol Metab2016;31:328-35, Cheol Ryong Ku et al.)
Ji-Young Cha Endocrinology and Metabolism.2016; 31(3): 480. CrossRef
- Adrenal gland
- Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
-
Youngki Lee, Cheol Ryong Ku, Eui-Hyun Kim, Jae Won Hong, Eun Jig Lee, Sun Ho Kim
-
Endocrinol Metab. 2014;29(3):280-292. Published online September 25, 2014
-
DOI: https://doi.org/10.3803/EnM.2014.29.3.280
-
-
4,270
View
-
52
Download
-
12
Web of Science
-
13
Crossref
-
Abstract
PDFPubReader
- Background
Cabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resistance, and the early characteristics of these patients remain unclear. We analyzed early indicators predicting long-term response to cabergoline. MethodsWe retrospectively reviewed the cases of 44 patients with macroprolactinomas who received cabergoline as first-line treatment; the patients were followed for a median of 16 months. The influence of various clinical parameters on outcomes was evaluated. ResultsForty patients (90.9%) were treated medically and displayed tumor volume reduction (TVR) of 74.7%, a prolactin normalization (NP) rate of 81.8%, and a complete response (CR; TVR >50% with NP, without surgery) rate of 70.5%. Most patients (93.1%) with TVR ≥25% and NP at 3 months eventually achieved CR, whereas only 50% of patients with TVR ≥25% without NP and no patients with TVR <25% achieved CR. TVR at 3 months was strongly correlated with final TVR (R=0.785). Patients with large macroadenomas exhibited a low NP rate at 3 months, but eventually achieved TVR and NP rates similar to those of patients with smaller tumors. Surgery independently reduced the final dose of cabergoline (β=-1.181 mg/week), and two of four patients who underwent surgery were able to discontinue cabergoline. ConclusionDetermining cabergoline response using TVR and NP 3 months after treatment is useful for predicting later outcomes. However, further cabergoline administration should be considered for patients with TVR >25% at 3 months without NP, particularly those with huge prolactinomas, because a delayed response may be achieved. As surgery can reduce the cabergoline dose necessary for successful disease control, it should be considered for cabergoline-resistant patients.
-
Citations
Citations to this article as recorded by
- Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
Irena A. Ilovayskaya, Gulnar R. Vagapova Almanac of Clinical Medicine.2024; 51(7): 397. CrossRef - Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
Stephan Petersenn, Maria Fleseriu, Felipe F. Casanueva, Andrea Giustina, Nienke Biermasz, Beverly M. K. Biller, Marcello Bronstein, Philippe Chanson, Hidenori Fukuoka, Monica Gadelha, Yona Greenman, Mark Gurnell, Ken K. Y. Ho, Jürgen Honegger, Adriana G. Nature Reviews Endocrinology.2023; 19(12): 722. CrossRef - Outcome Measures for Medical and Surgical Treatment of Prolactinomas. Is the Role of Surgery Underestimated?
Andrius Anuzis, Kevin O. Lillehei Journal of Neurological Surgery Part B: Skull Base.2023;[Epub] CrossRef - Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Zixiang Cong, Chiyuan Ma Chinese Neurosurgical Journal.2022;[Epub] CrossRef - Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors
Renato Cozzi, Maria Rosaria Ambrosio, Roberto Attanasio, Claudia Battista, Alessandro Bozzao, Marco Caputo, Enrica Ciccarelli, Laura De Marinis, Ernesto De Menis, Marco Faustini Fustini, Franco Grimaldi, Andrea Lania, Giovanni Lasio, Francesco Logoluso, M European Journal of Endocrinology.2022; 186(3): P1. CrossRef - Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma
Kyungwon Kim, Yae Won Park, Daham Kim, Sung Soo Ahn, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Cheol Ryong Ku The Journal of Clinical Endocrinology & Metabolism.2021; 106(2): e615. CrossRef - Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas
Ji Yong Park, Wonsuk Choi, A Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Woo-Youl Jang, Shin Jung, Ho-Cheol Kang Pituitary.2021; 24(6): 955. CrossRef - Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications
Betina Biagetti, Rafael Simò International Journal of Molecular Sciences.2021; 22(20): 11247. CrossRef - A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas
Rakesh Mishra, SubhasK Konar, Adesh Shrivastava, Pradeep Chouksey, Sumit Raj, Amit Agrawal Indian Journal of Endocrinology and Metabolism.2021; 25(6): 493. CrossRef - Predictors of dopamine agonist resistance in prolactinoma patients
Elle Vermeulen, Jean D’Haens, Tadeusz Stadnik, David Unuane, Kurt Barbe, Vera Van Velthoven, Sven Gläsker BMC Endocrine Disorders.2020;[Epub] CrossRef - The Role of Dopamine Agonists in Pituitary Adenomas
Erica A. Giraldi, Adriana G. Ioachimescu Endocrinology and Metabolism Clinics of North America.2020; 49(3): 453. CrossRef - Prevalence of Thyroid Disease in Patients Surgically Treated for Pituitary Disease
Kim, Cho, Ku, Jung, Moon, Kim, Shin, Kim, Lee Journal of Clinical Medicine.2019; 8(8): 1142. CrossRef - Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
- Adrenal gland
- Characteristics of Acromegaly in Korea with a Literature Review
-
Jae Won Hong, Cheol Ryong Ku, Sun Ho Kim, Eun Jig Lee
-
Endocrinol Metab. 2013;28(3):164-168. Published online September 13, 2013
-
DOI: https://doi.org/10.3803/EnM.2013.28.3.164
-
-
3,697
View
-
50
Download
-
12
Crossref
-
Abstract
PDFPubReader
Acromegaly is a slowly progressive disease caused by excessive growth hormone (GH), which is related to a GH secreting pituitary tumor in most cases. Herein, we describe the epidemiology, clinical characteristics, and treatment of acromegaly in Korea with a literature review. The average annual incidence of acromegaly in Korea was 3.9 cases per million people, which was within the range of previous Western studies. The primary treatment for acromegaly was also transsphenoidal adenomectomy, which accounted for 90.4% of patients whose primary therapeutic options were known. The overall surgical remission rates were 89%, 87%, 64%, 70%, and 50% for modified Hardy classification I, II, IIIA, IIIB, and IV, respectively. An updated and larger study regarding the treatment outcome of medical/radiotherapy in Korean acromegalic patients is needed.
-
Citations
Citations to this article as recorded by
- Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study
Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park European Journal of Endocrinology.2023; 189(3): 363. CrossRef - Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea
Jiwon Kim, Namki Hong, Jimi Choi, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Sin Gon Kim, Cheol Ryong Ku Endocrinology and Metabolism.2023; 38(6): 690. CrossRef - Selective screening of patients with associated somatic diseases as a method of early detection of acromegaly
M. B. Antsiferov, V. S. Pronin, T. M. Alekseeva, O. A. Ionova, E. Y. Martynova, Yu. E. Poteshkin, N. A. Chubrova, K. Y. Zherebchikova Problems of Endocrinology.2021; 67(1): 20. CrossRef - Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee Endocrinology and Metabolism.2020; 35(2): 206. CrossRef - Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study
Xiaopeng Guo, Kailu Wang, Siyue Yu, Lu Gao, Zihao Wang, Huijuan Zhu, Bing Xing, Shuyang Zhang, Dong Dong Frontiers in Endocrinology.2020;[Epub] CrossRef - Epidemiología de la acromegalia en Ecuador
Enrique López Gavilanez, Kempis Guerrero Franco, Narcisa Solórzano Zambrano, Manuel Navarro Chávez, Camilo López Estrella, Luis Vaca Burbano, Eduardo Marriott Díaz Endocrinología y Nutrición.2016; 63(7): 333. CrossRef - A magnetic resonance imaging‐based classification system for indication of trans‐sphenoidal hypophysectomy in canine pituitary‐dependent hypercortisolism
A. Sato, T. Teshima, H. Ishino, Y. Harada, T. Yogo, N. Kanno, D. Hasegawa, Y. Hara Journal of Small Animal Practice.2016; 57(5): 240. CrossRef - Epidemiology of acromegaly in Ecuador
Enrique López Gavilanez, Kempis Guerrero Franco, Narcisa Solórzano Zambrano, Manuel Navarro Chávez, Camilo López Estrella, Luis Vaca Burbano, Eduardo Marriott Díaz Endocrinología y Nutrición (English Edition).2016; 63(7): 333. CrossRef - An Association Study Between Gene Polymorphisms of Folic Acid Metabolism Enzymes and Biochemical and Hormonal Parameters in Acromegaly
Aslı Tetik Vardarlı, Ayhan Zengi, Vildan Bozok Çetintaş, Muammer Karadeniz, Sadık Tamsel, Ali Şahin Küçükaslan, Timur Köse, Füsun Saygılı, Zuhal Eroglu Genetic Testing and Molecular Biomarkers.2015; 19(8): 431. CrossRef - Diagnosis, treatment and clinical perspectives of acromegaly
Ferdinand Roelfsema, Gerrit van den Berg Expert Review of Endocrinology & Metabolism.2015; 10(6): 619. CrossRef - Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
S. O. Chin, C. H. Chung, Y.-S. Chung, B.-J. Kim, H. Y. Kim, I.-J. Kim, J. G. Kim, M.-S. Kim, S.-Y. Kim, E. J. Lee, K. Y. Lee, S.-W. Kim BMJ Open.2015; 5(6): e006898. CrossRef - Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee Endocrinology and Metabolism.2014; 29(3): 251. CrossRef
- A Case of Pituitary Adenoma with Simultaneous Secretion of TSH and GH.
-
Eun Young Lee, Cheol Ryong Ku, Hyun Min Kim, Woo Kyoung Lee, Jung Soo Lim, Sena Hwang, Do Hwan Kim, Dong Yeob Shin, Eun Jig Lee
-
Endocrinol Metab. 2011;26(2):160-165. Published online June 1, 2011
-
DOI: https://doi.org/10.3803/EnM.2011.26.2.160
-
-
2,978
View
-
30
Download
-
2
Crossref
-
Abstract
PDF
- Thyrotropin (TSH)-secreting pituitary adenoma is a very rare disease. In one-quarter of patients suffering from this disease, the pituitary tumor secretes other anterior pituitary hormones. Herein, we report a case of pituitary adenoma with simultaneous secretion of TSH and growth hormone (GH). A 34-year-old female visitied local hospital complaining of sweating, intermittent palpitation, and weight loss of 8 kg within 1 year. The patient had undergone trans-sphenoidal surgery 3 years prior for resolution of a TSH and GH co-secreting pituitary adenoma. She had been administered somatostatin analogue prior to visiting our hospital. The patient's GH levels were suppressed to below 1 ng/mL on the 75 g oral glucose tolerance test, and her basal insulin-like growth factor-I (IGF-I) level was within normal range. Thyroid function tests demonstrated increased levels of both free thyroxine and TSH. Sella-MRI revealed pituitary adenoma at the floor of the pituitary fossa, approximately 2 cm in height. Therefore, she was diagnosed with residual TSH-secreting pituitary adenoma. The patient again underwent trans-sphenoidal surgery and entered complete remission, based on hormone levels and MRI findings.
-
Citations
Citations to this article as recorded by
- Endoscopic Transsphenoidal Surgery of Pituitary Adenomas: Preliminary Results of the Neurosurgery Service of Hospital Cristo Redentor
Gerson Perondi, Afonso Mariante, Fernando Azambuja, Gabriel Frizon Greggianin, Wanderson William dos Santos Dias, Giulia Pinzetta Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery.2023; 42(02): e89. CrossRef - A case of a co-secreting TSH and growth hormone pituitary adenoma presenting with a thyroid nodule
Laura Hamilton Adams, Derick Adams Endocrinology, Diabetes & Metabolism Case Reports.2018;[Epub] CrossRef
- Correlation between Pituitary Insufficiency and Magnetic Resonance Imaging Finding in Non-Functioning Pituitary Adenomas.
-
Hyun Min Kim, Cheol Ryong Ku, Eun Young Lee, Woo Kyung Lee, Jung Soo Lim, Sena Hwang, Mi Jung Lee, Seung Ku Lee, Sun Ho Kim, Eun Jig Lee
-
Endocrinol Metab. 2010;25(4):310-315. Published online December 1, 2010
-
DOI: https://doi.org/10.3803/EnM.2010.25.4.310
-
-
2,050
View
-
28
Download
-
1
Crossref
-
Abstract
PDF
- BACKGROUND
Non-functioning pituitary adenomas (NFPAs) are characterized by the absence of clinical and biochemical evidence of pituitary hormone hypersecretion, and these tumors constitute approximately one third of all the tumors of the anterior pituitary. Recently, hormonal deficiencies have gradually evolved to become the leading presenting signs and symptoms in patients with NFPAs. We investigated pituitary hormonal insufficiencies according to the magnetic resonance imaging (MRI) findings in patients with NFPA. METHODS: We evaluated the patients who were newly diagnosed with NFPA from 1997 through 2009. Among them, we analyzed 387 patients who were tested for their combined pituitary function and who underwent MRI. The severity of the hypopituitarism was determined by the number of deficient axes of the pituitary hormones. On the MRI study, the maximal diameter of the tumor, Hardy's classification, the thickness of the pituitary gland and the presence of stalk compression were evaluated. RESULTS: The mean age was 46.85 +/- 12.93 years (range: 15-86) and 186 patients (48.1%) were male. As assessed on MRI, the tumor diameter was 27.87 +/- 9.93 mm, the thickness of the normal pituitary gland was 1.42 +/- 2.07 mm and stalk compression was observed in 201 patients (51.9%). Hypopituitarism was observed in 333 patients (86.0%). Deficiency for each pituitary hormone was most severe in the patients with Hardy type IIIA. Hypopituitarism was severe in the older age patients (P = 0.001) and the patients with a bigger tumor size (P < 0.001) and the presence of stalk compression (P < 0.001). However, the patients who had a thicker pituitary gland showed less severe hypopituitarism (P < 0.001). Multivariate analysis showed that age, tumor diameter and the thickness of pituitary gland were important determinants for pituitary deficiency (P = 0.004, P < 0.001, P = 0.022, respectively). CONCLUSION: The results suggest that the hormonal deficiencies in patient with NFPA were correlated with the MRI findings, and especially the tumor diameter and preservation of the pituitary gland.
-
Citations
Citations to this article as recorded by
- Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas
Daham Kim, Cheol Ryong Ku, Se Hee Park, Ju Hyung Moon, Eui Hyun Kim, Sun Ho Kim, Eun Jig Lee World Neurosurgery.2018; 115: e464. CrossRef
- A Case of Graves' Disease Presenting with Chorea.
-
Cheol Ryong Ku, Hyung Jun Park, Sung Jin Hong, Dong Yeob Shin, Jin Ha Lee, Moon Jae Chung, Mi Ae Cho, Tae Woong Noh, Byung In Lee, Eun Jig Lee
-
J Korean Endocr Soc. 2008;23(5):342-346. Published online October 1, 2008
-
DOI: https://doi.org/10.3803/jkes.2008.23.5.342
-
-
2,002
View
-
20
Download
-
2
Crossref
-
Abstract
PDF
- Hyperthyroidism is invariably accompanied by nervous system dysfunction. Specifically, irritability, emotional lability, and hyperkinesia are the signs and symptoms most frequently observed. In rare instances, chorea and/or choreoathetosis are associated with hyperthyroidism. Full evaluation for the etiology of chorea is necessary prior to initiating treatment. We recently encountered a 42-year-old female who initially presented with hyperthyroidism and showed subsequent development of progressive generalized chorea. The patient was diagnosed with chorea secondary to Graves' disease after exclusion of other causes of chorea and improved after the initiation of pulse administration of intravenous methylprednisolone sodium succinate (Solu-medrol(R), 1000 mg for 5 days) and oral antithyroid medication. This treatment strategy resulted in the resolution of involuntary movements. The steroid administration was eventually tapered, and the patient has been maintained on antithyroid and steroid therapy with considerable success since the initiation of treatment.
-
Citations
Citations to this article as recorded by
- Unilateral upper limb chorea associated with hyperthyroidism: A case report and literature review
Wei Chen, Bin Wu, Hongna An, Kaiying Zheng, Daming Zhai, Jiahua Zang, Xiaobing Wu Frontiers in Neurology.2022;[Epub] CrossRef - Anti-Thyroid Peroxidase/Anti-Thyroglobulin Antibody-Related Neurologic Disorder Responsive to Steroids Presenting with Pure Acute Onset Chorea
Ritwik Ghosh, Subhankar Chatterjee, Souvik Dubey, Alak Pandit, Biman Kanti Ray, Julián Benito-León Tremor and Other Hyperkinetic Movements.2020;[Epub] CrossRef
- The Characteristics and Follow-up of Pituitary Incidentaloma.
-
Cheol Ryong Ku, Eun Jig Lee
-
J Korean Endocr Soc. 2008;23(2):109-110. Published online April 1, 2008
-
DOI: https://doi.org/10.3803/jkes.2008.23.2.109
-
-
Abstract
PDF
- No abstract available.
|